Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections

Ethical principles should prevail in the collection, testing and use of COVID-19 convalescent plasma (CCP) for human research in low- and middle- income countries. To appropriately guarantee safety, only blood establishments that comply with recognized quality standards should collect CCP.

Detalles Bibliográficos
Autores principales: Epstein, Jay, Martin Smid, W., Wendel, Silvano, Somuah, Daniel, Burnouf, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642349/
https://www.ncbi.nlm.nih.gov/pubmed/33298976
http://dx.doi.org/10.1038/s41541-020-00256-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642349/
https://www.ncbi.nlm.nih.gov/pubmed/33298976
http://dx.doi.org/10.1038/s41541-020-00256-6

Ejemplares similares